Trade now with Barclays Stockbrokers
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£23,447,104 |
Nicolas Loebel |
3,538,991 |
£530,849 |
Junaid Bajwa |
1,193,697 |
£179,054 |
Jean Duvall |
1,163,529 |
£174,529 |
Jean Charest |
353,356 |
£53,003 |
Simon Sinclair |
256,327 |
£38,449 |
Carolyn Cross |
119,258,222 |
£17,888,733 |
M&G Plc |
67,254,901 |
£10,088,235 |
hInsight-NX, LLC |
42,272,654 |
£6,340,898 |
Robert Cross |
37,772,652 |
£5,665,898 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,265,882 |
CRUX Asset Management |
9,298,090 |
£1,394,714 |
Chelverton Asset Management |
7,957,311 |
£1,193,597 |
16:35 |
100 @ 15.00p |
16:35 |
100 @ 15.00p |
14:04 |
14,129 @ 14.99p |
11:25 |
71,000 @ 14.70p |
12:13 |
20,000 @ 15.00p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research